Transbronchial EBUS-guided TBNA and Cryobiopsy of Mediastinal Lymph Nodes in Patients Nonsuspicious for Lung Cancer, Using Different Cryoprobe Freezing Times

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

EBUS-guided cryobiopsy of mediastinal and hilar lymph nodes has shown to be a useful diagnostic tool to obtain tissue for histological analysis and further targeted therapies in lung malignancies. Due to the large size and better quality of the tissue samples, a higher diagnostic yield than with transbronchial needle aspiration (TBNA) can be expected, especially in non-solid tumors. In previous studies different biopsy protocols were used. The freezing time of cryoprobe (which defines the sample sizes) ranged from 3 to 7 s and the number of biopsies was between 1 and 4 samples. It is therefore unclear what freezing times and biopsy frequency are required to obtain the best histological information.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• At least one mediastinal lesion or hilar 1 cm or longer in the short axis requiring diagnostic bronchoscopy

• Age between 18 and 90 years

• Written informed consent after participant's information

Locations
Other Locations
Switzerland
Jürgen Hetzel
RECRUITING
Basel
Contact Information
Primary
Carolin Steinack
carolin.steinack@usz.ch
0041 44 255 8689
Time Frame
Start Date: 2025-03-07
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 136
Treatments
Active_comparator: group 6 sec
EBUS-guided CBs of mediastinal/hilar lymph nodes will be done with 6 seconds of cryoprobe freezing time (group 6sec.) before the biopsy together with the whole EBUS bronchoscope is extracted.
Active_comparator: group 3 sec
EBUS-guided CBs of mediastinal/hilar lymph nodes will be done with 3 seconds of cryoprobe freezing time (group 3sec.) before the biopsy together with the whole EBUS bronchoscope is extracted.
Related Therapeutic Areas
Sponsors
Collaborators: Réseau Hospitalier Neuchâtelois, Spital Uster AG, Uster, Switzerland, Clinique des Grangettes, Chêne-Bougeries, Hôpital du Valais, Insel Gruppe AG, University Hospital Bern, Kantonsspital Winterthur KSW, Ospedale Regionale Bellinzona e Valli, HUG - Hôpitaux universitaires de Genève, Kantonsspital Chur, Switzerland, Aarau Cantonal Hospital (KSA), Unispital Basel, University of Lausanne Hospitals, Waid City Hospital, Zurich, Cantonal Hospital of St. Gallen
Leads: University of Zurich

This content was sourced from clinicaltrials.gov